The GREENFUND - we're buying the dip, big time, and here's why., page-122

If you just look at the efficacy of the drug ( ignoring both Aus and US vehicles ) ..... then it is a huge success. The drug reduces lesions in line with the best medicines available on the market today... that is a fact from the Q2 results - from both Aus and US sites for the 5% once a day.

The other prescription drugs that are available, either peel your skin off by burning, or contain nasty chemicals, so nasty... that pregnant women are not allowed to use the drug because it causes known birth defects. These are the market leaders, and these are what BOT is up against?

I think every dermatologist on the face of the planet is going to recommend the BOT product as a first point of call.... because so far

1. It has proven as / if not more effective ( against non inflamed pimples ) than the market leaders...... and

2. It has no serious side effects, so they are not going too have patients with skin burnt off, or not being able to have children etc.....

There is no way they would give a drug to a teenage girl that causes birth defects, over one without serious complications. BOT has the first effective drug created in decades

Ignore the facts at your peril.... It's bad that the SP tanked..... but it's also great because it's a winner and the market has read it incorrectly
you can buy more at half price, and just need to hang on until the P3 results for the pimple product, or the other P2 results for the alternate pipeline products.